PC-14Homo sapiens (Human)Cancer cell line

Also known as: PC14, PC 14

🤖 AI SummaryBased on 16 publications

Quick Overview

Human lung adenocarcinoma cell line with EGFR mutations and potential for cancer research.

Detailed Summary

PC-14 is a human lung adenocarcinoma cell line derived from Japanese patients. It is known for harboring specific EGFR mutations, which are critical in the development and progression of non-small cell lung cancer (NSCLC). The cell line has been utilized in studies examining the genetic heterogeneity of EGFR mutations and their implications in cancer therapy. Research on PC-14 has contributed to understanding the role of EGFR mutations in drug sensitivity and resistance, particularly in the context of targeted therapies like gefitinib. Additionally, PC-14 has been part of studies investigating the molecular mechanisms underlying cancer progression and the identification of potential therapeutic targets.

Research Applications

EGFR mutation analysisCancer drug sensitivity testingGenetic heterogeneity studiesTargeted therapy research

Key Characteristics

EGFR mutationsLung adenocarcinoma originJapanese patient derivation
Generated on 6/17/2025

Basic Information

Database IDCVCL_1640
SpeciesHomo sapiens (Human)
Tissue SourceLymph node[UBERON:UBERON_0000029]

Donor Information

Age45
Age CategoryAdult
SexMale
Raceasian

Disease Information

DiseaseLung adenocarcinoma
LineageLung
SubtypeLung Adenocarcinoma
OncoTree CodeLUAD

DepMap Information

Source TypeRIKEN
Source IDACH-000030_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Arg248Gln (c.743G>A)UnspecifiedSomatic mutation acquired during proliferationPubMed=20575032
MutationSimpleEGFRp.Glu746_Ala750del (c.2235_2249del15)Unspecified-from parent cell line PC-9

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
11
D13S317
8
D16S539
9
D18S51
15
D21S11
29,30
D5S818
11
D7S820
10
D8S1179
11,15
FGA
23,25
TH01
7
TPOX
11
vWA
17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

Aberrant methylation and silencing of IRF8 expression in non-small cell lung cancer.

Shibata H., Ito T., Baba Y., Baba H.

Oncol. Lett. 8:1025-1030(2014).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity.

Igishi T., Burioka N., Nanba E., Shimizu E.

Cancer Biol. Ther. 13:369-378(2012).

Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.

Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.

Cancer Sci. 101:1891-1896(2010).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

A gene-alteration profile of human lung cancer cell lines.";

Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.

Hum. Mutat. 30:1199-1206(2009).

Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp.

Fukuyama S., Yokote A., Kobayashi K., Kanazawa M., Hagiwara K.

Cancer Res. 65:7276-7282(2005).

Correlation between DNA alterations and p53 and p16 protein expression in cancer cell lines.

Murai Y., Hayashi S., Takahashi H., Tsuneyama K., Takano Y.

Pathol. Res. Pract. 201:109-115(2005).

Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers.

Hirohashi S., Inazawa J., Imoto I.

Hum. Mol. Genet. 14:997-1007(2005).

Correlation between interleukin 6 production and tumor proliferation in non-small cell lung cancer.

Fujisawa T.

Cancer Immunol. Immunother. 53:786-792(2004).

TERC identified as a probable target within the 3q26 amplicon that is detected frequently in non-small cell lung cancers.

Yokoi S., Yasui K., Iizasa T., Imoto I., Fujisawa T., Inazawa J.

Clin. Cancer Res. 9:4705-4713(2003).

Short tandem repeat profiling provides an international reference standard for human cell lines.

Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.

Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).

Mutation and expression of the DCC gene in human lung cancer.";

Yokota J.

Neoplasia 2:300-305(2000).

Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes.

Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J.

Int. J. Oncol. 15:927-934(1999).

Establishment of a drug sensitivity panel using human lung cancer cell lines.

Kohara H., Harada M.

Acta Med. Okayama 53:67-75(1999).

Clonogenic patterns of human pulmonary adenocarcinoma cell lines (PC-9, PC-13 and PC-14) and how they influence the results of test for chemosensitivity to cisplatin in the human tumor clonogenic assay.

Hoshi A., Chen K.-M., Hamburger A.W.

Jpn. J. Clin. Oncol. 15:637-644(1985).

Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay.

Saijo N.

Cancer Chemother. Pharmacol. 27:263-270(1991).

Web Resources